Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, Almquist H, Loft A, Højgaard L, Federico M, Gallamini A, Smith P, Johnson P, Radford J, O'Doherty MJ. Barrington SF, et al. Among authors: federico m. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33. doi: 10.1007/s00259-010-1490-5. Epub 2010 May 27. Eur J Nucl Med Mol Imaging. 2010. PMID: 20505930
Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.
Luminari S, Cesaretti M, Tomasello C, Guida A, Bagni B, Merli F, Postiglione R, Mangone L, Versari A, Re F, De Lisi V, Ruffini L, Ferretti S, Cuneo A, Federico M. Luminari S, et al. Among authors: federico m. Leuk Lymphoma. 2011 Sep;52(9):1689-96. doi: 10.3109/10428194.2011.580475. Epub 2011 Jun 12. Leuk Lymphoma. 2011. PMID: 21663500
Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.
Gobbi PG, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V, Marchianò A, Gallamini A, Bolis S, Stelitano C, Levis A, Federico M, Angrilli F, Di Giulio G, Corazza GR. Gobbi PG, et al. Among authors: federico m. Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):396-402. doi: 10.1016/j.clml.2011.04.008. Epub 2011 Jun 12. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21729691
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW. Barrington SF, et al. Among authors: federico m. Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407. Epub 2016 Jan 8. Blood. 2016. PMID: 26747247 Free article.
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.
Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, Salles G, Meignan M. Trotman J, et al. Among authors: federico m. Lancet Haematol. 2014 Oct;1(1):e17-27. doi: 10.1016/S2352-3026(14)70008-0. Epub 2014 Sep 17. Lancet Haematol. 2014. PMID: 27030064
The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).
Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A. Chauvie S, et al. Among authors: federico m. Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28. Phys Med. 2016. PMID: 27133138
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Johnson P, et al. Among authors: federico m. N Engl J Med. 2016 Jun 23;374(25):2419-29. doi: 10.1056/NEJMoa1510093. N Engl J Med. 2016. PMID: 27332902 Free PMC article. Clinical Trial.
Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Johnson P, Trotman J, Federico M. Johnson P, et al. Among authors: federico m. N Engl J Med. 2016 Sep 8;375(10):999-1000. doi: 10.1056/NEJMc1609333. N Engl J Med. 2016. PMID: 27602676 Free article. No abstract available.
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.
Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J. Eichenauer DA, et al. Among authors: federico m. Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478. Epub 2017 Sep 14. Haematologica. 2017. PMID: 28912173 Free PMC article. Review.
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Van Zele E, Chartier L, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M, Meignan M. Cottereau AS, et al. Among authors: federico m. Blood. 2018 Mar 29;131(13):1456-1463. doi: 10.1182/blood-2017-07-795476. Epub 2018 Feb 1. Blood. 2018. PMID: 29437590 Free article. Clinical Trial.
761 results